» Articles » PMID: 8432869

Lack of HLA Class I Antigen Expression by Melanoma Cells SK-MEL-33 Caused by a Reading Frameshift in Beta 2-microglobulin Messenger RNA

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1993 Feb 1
PMID 8432869
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The lack of HLA class I antigen expression by the melanoma cell line SK-MEL-33 is caused by a unique lesion in beta 2-microglobulin (beta 2-mu). Sequencing of beta 2-mu mRNA detected a guanosine deletion at position 323 in codon 76 that causes a frameshift with a subsequent introduction of a stop codon at a position 54 base upstream of the normal position of the stop codon in the message. The loss of 18 amino acids and the change of 6 amino acids, including a cysteine at position 80 in the carboxy terminus of beta 2-mu, are likely to cause marked changes in the structure of the polypeptide. The latter may account for the inability of beta 2-mu to associate with HLA class I heavy chains and for its lack of reactivity with the anti-beta 2-mu mAb tested. HLA class I antigen expression on SK-MEL-33 cells was reconstituted after transfection with a wild-type B2m gene, therefore indicating that the abnormality of endogenous B2m gene is the only mechanism underlying lack of HLA class I antigen expression by SK-MEL-33 cells. The guanosine deletion in B2m gene was detected also in the melanoma tissue from which SK-MEL-33 cells had originated. Therefore, the molecular lesion identified in the SK-MEL-33 melanoma cell line is not caused by a mutation acquired during growth in vitro but is likely to reflect a somatic mutation during tumor progression.

Citing Articles

Cancer-Associated Fibroblasts Genes and Transforming Growth Factor Beta Pathway in Gastric Cancer for Novel Therapeutic Strategy.

Minoura H, Okamoto R, Hiki N, Yamashita K Cancers (Basel). 2025; 17(5).

PMID: 40075643 PMC: 11899367. DOI: 10.3390/cancers17050795.


The immune-related role of beta-2-microglobulin in melanoma.

Wang C, Wang Z, Yao T, Zhou J, Wang Z Front Oncol. 2022; 12:944722.

PMID: 36046045 PMC: 9421255. DOI: 10.3389/fonc.2022.944722.


Cancer stem cells and macrophages: molecular connections and future perspectives against cancer.

Aramini B, Masciale V, Grisendi G, Banchelli F, DAmico R, Maiorana A Oncotarget. 2021; 12(3):230-250.

PMID: 33613850 PMC: 7869576. DOI: 10.18632/oncotarget.27870.


Prostate cancer health disparities: An immuno-biological perspective.

Kumar S, Singh R, Malik S, Manne U, Mishra M Cancer Lett. 2017; 414:153-165.

PMID: 29154974 PMC: 5743619. DOI: 10.1016/j.canlet.2017.11.011.


The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors.

Guerrero A, Moyes J, Cooper L Chin J Cancer. 2014; 33(9):421-33.

PMID: 25189715 PMC: 4190432. DOI: 10.5732/cjc.014.10100.


References
1.
Suggs S, Wallace R, Hirose T, Kawashima E, Itakura K . Use of synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA sequences for human beta 2-microglobulin. Proc Natl Acad Sci U S A. 1981; 78(11):6613-7. PMC: 349099. DOI: 10.1073/pnas.78.11.6613. View

2.
Del Sal G, Manfioletti G, Schneider C . The CTAB-DNA precipitation method: a common mini-scale preparation of template DNA from phagemids, phages or plasmids suitable for sequencing. Biotechniques. 1989; 7(5):514-20. View

3.
Pellegrino M, Ng A, Russo C, Ferrone S . Heterogeneous distribution of the determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. Transplantation. 1982; 34(1):18-23. DOI: 10.1097/00007890-198207000-00004. View

4.
de Preval C, MACH B . The absence of beta 2-microglobulin in Daudi cells: active gene but inactive messenger RNA. Immunogenetics. 1983; 17(2):133-40. DOI: 10.1007/BF00364753. View

5.
Zweig S, Shevach E . Production and properties of monoclonal antibodies to guinea pig Ia antigens. Methods Enzymol. 1983; 92:66-85. DOI: 10.1016/0076-6879(83)92010-4. View